Actively Recruiting
Phase 1 Study of Azercabtagene Zapreleucel IV Infusion for B-cell Mediated Autoimmune Disorders Assessing Safety and Activity
Led by TG Therapeutics, Inc. · Updated on 2026-10-27
100
Participants Needed
8
Research Sites
108 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying Azercabtagene zapreleucel azer-cel to find the recommended phase 2 dose for treating people with B-cell mediated autoimmune disorders. This phase 1, open-label trial aims to assess the safety and clinical activity of azer-cel in these participants. The study is led by TG Therapeutics, Inc. and focuses on treatment effects and dose-limiting toxicities within the first 28 days after infusion. Participants will receive one intravenous infusion of azer-cel on Day 0 at varying dose levels. The study is non-randomized and open-label, meaning all participants will receive the experimental drug. The trial monitors several outcomes up to two years, including adverse events, pharmacokinetics and pharmacodynamics of azer-cel, disability progression or improvement, brain imaging changes, vision measures, and quality of life scores related to autoimmune conditions. During the trial, participants undergo multiple assessments including clinical evaluations, laboratory tests, and brain MRI scans over a follow-up period of up to 720 days. Researchers will track side effects, drug levels in the blood, and changes in neurological disability and quality of life. The main outcome is the number of participants experiencing dose-limiting toxicities in the first 28 days. Participants are followed for up to about four years until the study ends in early 2029.
CONDITIONS
Brief Title
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Research Team
T
TG Therapeutics Clinical Support Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here